Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience.
Rughani MG. et al, (2011), J Plast Reconstr Aesthet Surg, 64, 1284 - 1290
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
Mitchell CL. et al, (2011), Cancer Chemother Pharmacol, 68, 631 - 641
Efficacy of Veliparib (ABT-888) Plus Temozolomide Versus Temozolomide Alone: a Randomized, Double-blind, Placebo-controlled Trial in Patients with Metastatic Melanoma
Middleton M. et al, (2011), EUROPEAN JOURNAL OF CANCER, 47, 8 - 8
Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater
Neoptolemos JP. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer.
Khan OA. et al, (2011), Br J Cancer, 104, 1822 - 1827
Adverse reactions to Patent Blue v dye used in sentinel lymph node biopsy for Melanoma
Rughani MG. et al, (2011), European Journal of Plastic Surgery, 34, 201 - 204
Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients.
Wang DD. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater
Neoptolemos JP. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.
Leijen S. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
Macaulay VM. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Does metabolic response at repeat PET/CT examination predict pathological response to neoadjuvant chemotherapy in oesophageal cancer?
Gillies RS. et al, (2011), BRITISH JOURNAL OF SURGERY, 98, 7 - 7
Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
Gillies RS. et al, (2011), BRITISH JOURNAL OF SURGERY, 98, 3 - 3
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
Khan OA. et al, (2011), Br J Cancer, 104, 750 - 755
Circulating melanoma cells and survival in metastatic melanoma.
Rao C. et al, (2011), Int J Oncol, 38, 755 - 760
Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
Gillies RS. et al, (2011), Eur Radiol, 21, 274 - 280
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
Khan OA. et al, (2011), British Journal of Cancer
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Leijen S. et al, (2011), Cancer Chemotherapy and Pharmacology, 1 - 10
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
Khan OA. et al, (2011), Br J Cancer, 104, 1822 - 1827